摘要
目的对盐酸文拉法辛缓释片治疗抑郁焦虑共病的临床效果进行评价分析。方法选择2019年1—12月在该院住院的80例抑郁焦虑共病患者作为临床研究对象,按照随机原则,将患者分为实验组和对照组,每组40例。实验组患者采用盐酸文拉法辛缓释片进行治疗,对照组患者采用盐酸帕罗西汀片进行治疗,对两组患者的临床治疗效果等进行比较和分析。结果经过为期8周的治疗,实验组患者临床治疗有效率为95.0%,明显高于对照组77.50%,差异有统计学意义(χ^(2)=5.165,P<0.05)。对两组患者治疗前后的HAMD、HAMA评分情况进行比较,在治疗前,两组评分对比,差异无统计学意义(P>0.05)。经过为期8周的治疗,实验组和对照组的HAMD、HAMA评分对比治疗前均明显降低,差异有统计学意义(P<0.05)。在治疗4周末,实验组显著低于对照组HAMD、HAMA评分情况,差异有统计学意义(P<0.05)。在治疗8周末,实验组显著低于对照组HAMD、HAMA评分情况,差异有统计学意义(P<0.05)。从不良反应发生情况来看,实验组不良反应发生率为17.50%,明显低于对照组(37.50%),差异有统计学意义(P<0.05)。结论针对抑郁焦虑共病患者的治疗,使用盐酸文拉法辛缓释片能够有效提升临床治疗有效率,改善HAMD、HAMA评分水平,降低不良反应发生率,具有良好的临床治疗效果。
Objective To evaluate and analyze the clinical effects of venlafaxine hydrochloride sustained-release tablets in the treatment of comorbid depression and anxiety.Methods From January to December 2019,80 patients with comorbid depression and anxiety who were hospitalized in the hospital were selected as clinical research objects.According to the principle of randomization,the patients were divided into experimental and control groups,each with 40 cases.Patients in the experimental group were treated with venlafaxine hydrochloride sustained-release tablets,and patients in the control group were treated with paroxetine hydrochloride tablets.The clinical treatment effects of the two groups of patients were compared and analyzed.Results After 8 weeks of treatment,the clinical treatment effective rate of the experimental group was 95.00%,which was significantly higher than that of the control group 77.50%,the difference was statistically significant(χ^(2)=5.165,P<0.05).The HAMD and HAMA scores of the two groups of patients before and after treatment were compared.Before treatment,the difference was not statistically significant(P>0.05).After 8 weeks of treatment,the HAMD and HAMA scores of the experimental group and the control group were significantly reduced,the difference were statistically significant(P<0.05).At the 4th weekend of treatment,the experimental group were significantly lower than the control group's HAMD and HAMA scores,the difference were statistically significant(P<0.05).At the 8th weekend of treatment,the experimental group were significantly lower than the control group's HAMD and HAMA scores,the difference were statistically significant(P<0.05).In terms of the occurrence of adverse reactions,the incidence of adverse reactions in the experimental group was 17.50%,which was significantly lower than that in the control group 37.50%,the difference was statistically significant(P<0.05).Conclusion For the treatment of patients with comorbid depression and anxiety,the use of venlafaxine hydrochloride sustained-release tablets can effectively improve the clinical treatment efficiency,improve the HAMD and HAMA score levels,reduce the incidence of adverse reactions,and have a good clinical treatment effect.
作者
刘霞
庄晓华
LIU Xia;ZHUANG Xiao-hua(Linyi Mental Health Center,Linyi,Shandong Province,276005 China)
出处
《世界复合医学》
2021年第2期1-4,共4页
World Journal of Complex Medicine
关键词
盐酸文拉法辛缓释片
抑郁焦虑共病
临床疗效
Venlafaxine hydrochloride sustained-release tablets
Depression and anxiety comorbidity
Clinical efficacy
